Am J Cardiol. 2009;103:1530 6. 554. Rittger H, Hochadel M, Behrens S, et al. Age-related differences in diag- nosis, treatment and outcome of acute coronary syndromes: results from the German ALKK registry. EuroIntervention. 2012;7:1197 205. 555. Birkhead JS, Weston CF, Chen R. Determinants and outcomes of coro- nary angiography after non-ST-segment elevation myocardial infarction. A cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Heart. 2009;95:1593 9. 556. Casella G, Scorcu G, Cassin M, et al. Elderly patients with acute coro- nary syndromes admitted to Italian intensive cardiac care units: a Blitz-3 Registry sub-analysis. J Cardiovasc Med (Hagerstown). 2012;13:165 74. 557. Bardakci H, Cheema FH, Topkara VK, et al. Discharge to home rates are significantly lower for octogenarians undergoing coronary artery bypass graft surgery. Ann Thorac Surg. 2007;83:483 9. 558. Krane M, Voss B, Hiebinger A, et al. Twenty years of cardiac surgery in patients aged 80 years and older: risks and benefits. Ann Thorac Surg. 2011;91:506 13. 559. Panesar SS, Athanasiou T, Nair S, et al. Early outcomes in the elderly: a meta-analysis of 4921 patients undergoing coronary artery bypass grafting comparison between off-pump and on-pump techniques. Heart. 2006;92:1808 16. 560. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625 34. 561. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment ele- vation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096 104. 562. Segev A, Strauss BH, Tan M, et al. Prognostic significance of admis- sion heart failure in patients with non-ST-elevation acute coronary syn- dromes (from the Canadian Acute Coronary Syndrome Registries). Am J Cardiol. 2006;98:470 3. 563. Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational stud- ies. Eur J Heart Fail. 2011;13:773 84. 564. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multi- vessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190 7. 565. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961 72. 566. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coro- nary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352: 2174 83. 567. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percuta- neous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006;82:1420 8. 568. Kunadian V, Pugh A, Zaman AG, et al. Percutaneous coronary interven- tion among patients with left ventricular systolic dysfunction: a review and metaanalysis of 19 clinical studies. Coron Artery Dis. 2012;23:469 79. 569. Shah R, Thomson A, Atianzar K, et al. Percutaneous left ventricular sup- port for high-risk PCI and cardiogenic shock: who gets what? Cardiovasc Revasc Med. 2012;13:101 5. 570. Maini B, Naidu SS, Mulukutla S, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary inter- vention: The USpella Registry. Catheter Cardiovasc Interv. 2012; 80:717 25. 571. Froesch P, Martinelli M, Meier P, et al. Clinical use of temporary per- cutaneous left ventricular assist devices. Catheter Cardiovasc Interv. 2011;78:304 13. 572. Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54:2430 4. 573. Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a random- ized, controlled trial of elective balloon counterpulsation during high- risk percutaneous coronary intervention. Circulation. 2013;127:207 12. 574. Goldberg RJ, Yarzebski J, Spencer FA, et al. Thirty-year trends (1975- 2005) in the magnitude, patient characteristics, and hospital outcomes of patients with acute myocardial infarction complicated by ventricular fibrillation. Am J Cardiol. 2008;102:1595 601. 575. Gupta S, Pressman GS, Figueredo VM. Incidence of, predictors for, and mortality associated with malignant ventricular arrhythmias in non-ST elevation myocardial infarction patients. Coron Artery Dis. 2010;21:460 5. 576. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 1997;80: 35J 9J. 577. Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycar- dia. J Am Coll Cardiol. 2012;60:1993 2004. 578. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994;127:1139 44. 579. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. CardiacArrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071 8. 580. A comparison of antiarrhythmic-drug therapy with implantable defibril- lators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576 83. 581. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibril- lator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. 582. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormali- ties: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. [published correction appears in Circulation. 2009;120:e34-35]. Circulation. 2008;117:e350 408. 583. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Circulation. 2006;114:1088 132. 584. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and out- comes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30:2019 28. 585. Lean & MasterACLS.Available at: http://acls-algorithms.com/vfpulseless-vt. Accessed July 30, 2014. 586. Hreybe H, Saba S. Location of acute myocardial infarction and associ- ated arrhythmias and outcome. Clin Cardiol. 2009;32:274 7. 587. Newby KH, Pisano E, Krucoff MW, et al. Incidence and clinical rel- evance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. Circulation. 1996;94:2424 8. 588. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511 5. 589. Jeger RV, Urban P, Harkness SM, et al. Early revascularization is benefi- cial across all ages and a wide spectrum of cardiogenic shock severity: a pooled analysis of trials. Acute Card Care. 2011;13:14 20. 590. Lim HS, Farouque O,Andrianopoulos N, et al. Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. JACC Cardiovasc Interv. 2009;2:146 52. 591. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448 54. 592. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine ace- tate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297:1657 66. 593. Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004;164:1457 63. 594. Awad HH, Anderson FA Jr., Gore JM, et al. Cardiogenic shock compli- cating acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. Am Heart J. 2012;163:963 71. 595. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST- segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK? J Am Coll Cardiol. 2000;36:1091 6. 596. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779 89. 597. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardio- genic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30:2102 8. 598. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra- aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003; 108:951 7. 599. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clini- cal study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.Am Heart J. 2006;152. 469 8. 600. Seyfarth M, Sibbing D, Bauer I, et al.A randomized clinical trial to evalu- ate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584 8. 601. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consider- ation of the extent of coronary artery disease and benefits of revascular- ization. J Am Coll Cardiol. 2004;43:585 91. 602. Silva JA, Escobar A, Collins TJ, et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 1995;92:1731 6. 603. Elbarouni B, Ismaeil N, Yan RT, et al. Temporal changes in the manage- ment and outcome of Canadian diabetic patients hospitalized for non-ST- elevation acute coronary syndromes. Am Heart J. 2011;162:347 55. 604. Kristensen TS, Kofoed KF, Kuhl JT, et al. Prognostic implications of nonobstructive coronary plaques in patients with non-ST-segment eleva- tion myocardial infarction: a multidetector computed tomography study. J Am Coll Cardiol. 2011;58:502 9. 605. Sanchez PL, Morinigo JL, Pabon P, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart. 2004;90:264 9. 606. Ting HH, Chen AY, Roe MT, et al. Delay from symptom onset to hospi- tal presentation for patients with non-ST-segment elevation myocardial infarction. Arch Intern Med. 2010;170:1834 41. 607. Hasin T, Hochadel M, Gitt AK, et al. Comparison of treatment and out- come of acute coronary syndrome in patients with versus patients with- out diabetes mellitus. Am J Cardiol. 2009;103:772 8. 608. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glu- cose control in critically ill patients. N Engl J Med. 2009;360:1283 97. 609. Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1:379 86. 610. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interven- tional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349 56. 611. ChaseAJ, Fretz EB,WarburtonWP, et al.Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019 25. 612. Bakhai A, Collinson J, Flather MD, et al. Diabetic patients with acute coronary syndromes in the UK: high risk and under treated. Results from the prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). Int J Cardiol. 2005;100:79 84. 613. Groot MW, Head SJ, Bogers AJ, et al. Coronary revascularization in diabetic patients. A focus on the 3-year SYNTAX trial outcomes. Herz. 2012;37:281 6. 614. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percu- taneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432 40. 615. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multives- sel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575 81. 616. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for mul- tivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375 84. 617. Feit F, Manoukian SV, Ebrahimi R, et al. Safety and efficacy of bivali- rudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from theACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2008;51:1645 52. 618. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic out- comes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626 36. 619. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006 16. 620. Waters DD, Walling A, Roy D, et al. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. Am J Cardiol. 1986;58:465 9. 621. Kleiman NS, Anderson HV, Rogers WJ, et al. Comparison of outcome of patientswithunstableanginaandnon-Q-waveacutemyocardialinfarction Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e409 with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Am J Cardiol. 1996;77:227 31. 622. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002;105:322 7. 623. Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008;102:552 8. 624. Labinaz M, Mathias J, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary interven- tion: a pooled analysis of three randomized clinical trials. Eur Heart J. 2005;26:128 36. 625. Kim MS, Wang TY, Ou FS, et al. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. Am Heart J. 2010;160:951 7. 626. Adesanya AO, de Lemos JA, Greilich NB, et al. Management of peri- operative myocardial infarction in noncardiac surgical patients. Chest. 2006;130:584 96. 627. Berger PB, Bellot V, Bell MR, et al. An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac sur- gery. Am J Cardiol. 2001;87:1100 2. A6, A9. 628. Bertrand ME, Lablanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coro- nary arteriography. Circulation. 1982;65:1299 306. 629. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948 54. 630. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts futuredevelopmentofcoronaryarterydisease:astudyofwomenwithchest pain and normal coronary angiograms. Circulation. 2004;109:2518 23. 631. Gualandro DM, Calderaro D, Yu PC, et al. Acute myocardial infarction after noncardiac surgery. Arq Bras Cardiol. 2012;99:1060 7. 632. Gualandro DM, Yu PC, Calderaro D, et al. II Guidelines for periopera- tive evaluation of the Brazilian Society of Cardiology. Arq Bras Cardiol. 2011;96:1 68. 633. Villacorta JH, Castro IS, Godinho M, et al. B-type natriuretic peptide is predictive of postoperative events in orthopedic surgery. Arq Bras Cardiol. 2010; 95:743 8. 634. [Guidelines for unstable angina and non-ST-segment elevation myocar- dial infarction of the Brazilian Society of Cardiology (II Edition, 2007)]. Arq Bras Cardiol. 2007;89:e89 131. 635. Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol. 2006;48:1763 4. 636. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011;154:523 8. 637. Devereaux PJ, Chan MT, Alonso-Coello P, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012;307:2295 304. 638. Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. Clin Biochem. 2011;44:1021 4. 639. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after non- cardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2011;114:796 806. 640. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol. 2003;42: 1547 54. 641. Bursi F, Babuin L, Barbieri A, et al. Vascular surgery patients: periopera- tive and long-term risk according to theACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J. 2005;26:2448 56. 642. Devereaux PJ, Goldman L, Yusuf S, et al. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ. 2005;173:779 88. 643. Landesberg G, Beattie WS, Mosseri M, et al. Perioperative myocardial infarction. Circulation. 2009;119:2936 44. 644. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation. 2009;120:e169 276. 645. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release meto- prolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839 47. 646. McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. Eur Heart J. 2008;29:394 401. 647. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845 50. 648. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospec- tive validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043 9. 649. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarc- tion and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563 70. 650. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555 62. 651. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4:1032 43. 652. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal func- tion on the effects of early revascularization in non-ST-elevation myo- cardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009; 120:851 8. 653. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocar- dial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A col- laborative project of the United States Renal Data System/ National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399 406. 654. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular fil- tration rate, inflammation, and cardiovascular events after an acute coro- nary syndrome. Am Heart J. 2008;155:725 31. 655. Melloni C, Peterson ED, Chen AY, et al. Cockcroft-Gault versus modi- fication of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non- ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991 6. 656. Al SJ, Reddan DN, Williams K, et al. Prognostic implications of abnor- malities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974 80. 657. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285 95. 658. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in con- text. Eur J Heart Fail. 2003;5:537 44. 659. Skali H, Uno H, Levey AS, et al. Prognostic assessment of estimated glo- merular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J. 2011;162:548 54. 660. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584 90. 661. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369 79. 662. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357 65. 663. Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12 inhibi- tion by thienopyridines in chronic kidney disease: mechanisms, clini- cal relevance and pharmacological options. Nephrol Dial Transplant. 2013;28:1994 2002. 664. Park SH, Kim W, Park CS, et al.A comparison of clopidogrel responsive- ness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292 5. 665. Morel O, El GS, Jesel L, et al. Cardiovascular mortality in chronic kid- ney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399 408. 666. Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high- maintenance dose of clopidogrel: results of the effect of platelet inhibi- tion according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J. 2011;162:1018 25. 667. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialy- sis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9:2379 85. 668. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056 67. 669. Hutchinson-Jaffe AB, Goodman SG, Yan RT, et al. Comparison of base- line characteristics, management and outcome of patients with non-ST- segment elevation acute coronary syndrome in versus not in clinical trials. Am J Cardiol. 2010;106:1389 96. 670. Akhter N, Milford-Beland S, Roe MT, et al. Gender differences among patients with acute coronary syndromes undergoing percuta- neous coronary intervention in the American College of Cardiology- National Cardiovascular Data Registry (ACC-NCDR). Am Heart J. 2009;157:141 8. 671. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syn- dromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/ American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol. 2005;45:832 7. 672. Lansky AJ, Mehran R, Cristea E, et al. Impact of gender and antithrom- bin strategy on early and late clinical outcomes in patients with non- ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196 203. 673. Alexander KP, ChenAY, Newby LK, et al. Sex differences in major bleed- ing with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guide- lines) initiative. Circulation. 2006;114:1380 7. 674. Regitz-ZagrosekV, Blomstrom LC, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147 97. 675. Dey S, Flather MD, Devlin G, et al. Sex-related differences in the pre- sentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009;95:20 6. 676. Radovanovic D, Erne P, Urban P, et al. Gender differences in manage- ment and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. Heart. 2007;93:1369 75. 677. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54:1561 75. 678. Kaul P, Chang WC, Westerhout CM, et al. Differences in admission rates and outcomes between men and women presenting to emergency depart- ments with coronary syndromes. CMAJ. 2007;177:1193 9. 679. Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ. 1994;308:883 6. 680. Kreatsoulas C, Natarajan MK, Khatun R, et al. Identifying women with severe angiographic coronary disease. J Intern Med. 2010;268:66 74. 681. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical, character- istics, and mortality among patients with myocardial infarction present- ing without chest pain. JAMA. 2000;283:3223 9. 682. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009;169:843 50. 683. Truong QA, Murphy SA, McCabe CH, et al. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011;4:328 36. 684. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST- elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) sub- study. Circulation. 2004;109:580 6. 685. Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160:80 7. 686. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medi- cal care and early death after acute myocardial infarction. Circulation. 2008;118:2803 10. 687. Pauly DF, Johnson BD, Anderson RD, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascu- lar dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678 84. 688. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleed- ing in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556 66. 689. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J. 2004;25:1641 50. 690. Sidhu RB, Brown JR, Robb JF, et al. Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol. 2008;102:1482 6. 691. Ohlow MA, Secknus MA, von KH, et al. Incidence and outcome of fem- oral vascular complications among 18,165 patients undergoing cardiac catheterisation. Int J Cardiol. 2009;135:66 71. 692. Lansky AJ, Costa RA, Mooney M, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery dis- ease. J Am Coll Cardiol. 2005;45:1180 5. 693. Ng VG, Lansky AJ, Hermiller JB, et al. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol. 2011;107:841 8. 694. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. JAm Coll Cardiol. 2007;50:2111 6. 695. Bukkapatnam RN, Yeo KK, Li Z, et al. Operative mortality in women and men undergoing coronary artery bypass grafting (from the California Coronary Artery Bypass Grafting Outcomes Reporting Program). Am J Cardiol. 2010;105:339 42. 696. Kim C, Redberg RF, Pavlic T, et al. A systematic review of gender differ- ences in mortality after coronary artery bypass graft surgery and percuta- neous coronary interventions. Clin Cardiol. 2007;30:491 5. 697. Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;156:209 15. 698. LaPointe NM, ChenAY,Alexander KP, et al. Enoxaparin dosing and associ- ated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.Arch Intern Med. 2007;167:1539 44. 699. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042. ical practice guideline from the AABB. Ann Intern Med. 2012;157:49 58. 701. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfu- sion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555 62. 702. Alexander KP, Chen AY, Wang TY, et al. Transfusion practice and out- comes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155:1047 53. 703. Yang X, Alexander KP, Chen AY, et al. The implications of blood trans- fusions for patients with non-ST-segment elevation acute coronary syn- dromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490 5. 704. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemo- globin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042 9. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e411 705. Gonzalez-Ferrer JJ, Garcia-Rubira JC, Balcones DV, et al. Influence of hemoglobin level on in-hospital prognosis in patients with acute coro- nary syndrome. Rev Esp Cardiol. 2008;61:945 52. 706. Rousseau M, Yan RT, Tan M, et al. Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. Am J Cardiol. 2010;106:1417 22. 707. Younge JO, Nauta ST, Akkerhuis KM, et al. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syn- dromes. Am J Cardiol. 2012;109:506 10. 708. Shu DH, Ransom TP, O Connell CM, et al. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovasc Diabetol. 2006;5:8. 709. Levy PS, Quigley RL, Gould SA. Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxy- gen delivery. J Trauma. 1996;41:416 23. 710. Most AS, Ruocco NA Jr., Gewirtz H. Effect of a reduction in blood vis- cosity on maximal myocardial oxygen delivery distal to a moderate coro- nary stenosis. Circulation. 1986;74:1085 92. 711. Willis P, Voeltz MD. Anemia, hemorrhage, and transfusion in percutane- ous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;104:34C 8C. 712. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125:1424 31. 713. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syn- dromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854 64. 714. Manoukian SV. Predictors and impact of bleeding complications in percu- taneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;104:9C 15C. 715. Pham PA, Pham PT, Pham PC, et al. Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. Vasc Health Risk Manag. 2011;7:551 67. 716. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815 23. 717. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitionWith Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681 9. 718. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457 66. 719. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J. 2007;154:3 11. 720. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials proposal of a new classification. Am J Cardiol. 2007;99:288 90. 721. Schulman S, Kearon C. Definition of major bleeding in clinical inves- tigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692 4. 722. Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood trans- fusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1193 204. 723. Cheng S, Morrow DA, Sloan S, et al. Predictors of initial nontherapeu- tic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation. 2009;119:1195 202. 724. Campbell CL, Steinhubl SR, Hooper WC, et al. Bleeding events are associated with an increase in markers of inflammation in acute coro- nary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis. 2011;31:139 45. 725. Subherwal S, Bach RG, ChenAY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873 82. 726. Chatterjee S, Wetterslev J, Sharma A, et al. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diver- sity-adjusted study sequential analysis. JAMA Intern Med. 2013;173:132 9. 727. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598 660. 728. Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic sig- nificance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168:94 102. 729. Wang TY, Ou FS, Roe MT, et al. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in con- temporary clinical practice. Circulation. 2009;119:2454 62. 730. Hakim DA, Dangas GD, CaixetaA, et al. Impact of baseline thrombocyto- penia on the early and late outcomes after ST-elevation myocardial infarc- tion treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161:391 6. 731. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppres- sion using integrilin therapy (PURSUIT) trial experience. Circulation. 1999;99:2892 900. 732. Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia com- plicating treatment with intravenous glycoprotein IIb/IIIa receptor inhib- itors: a pooled analysis. Am Heart J. 2000;140:206 11. 733. Matthai WH Jr. Evaluation of thrombocytopenia in the acute coronary syndrome. Curr Opin Hematol. 2010;17:398 404. 734. Kilickiran AB, Oto A, Ozcebe O. Thrombocytopenia associated with antithrombotic therapy in patients with cardiovascular diseases: diagno- sis and treatment. Am J Cardiovasc Drugs. 2008;8:327 39. 735. Gore JM, Spencer FA, Gurfinkel EP, et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009;103:175 80. 736. Yeh RW, Wiviott SD, Giugliano RP, et al. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfraction- ated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007;100:1734 8. 737. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. Circulation. 2001;103:643 50. 738. Caixeta A, Dangas GD, Mehran R, et al. Incidence and clinical conse- quences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J. 2011;161:298 306. 739. Lopes RD, Ohman EM, Granger CB, et al. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based antico- agulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). Am J Cardiol. 2009;104:1285 91. 740. Jolicoeur EM, Ohman EM, Honeycutt E, et al. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. Am J Cardiol. 2009;104:292 7. 741. Baumann BM, Perrone J, Hornig SE, et al. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med. 2000;7:878 85. 742. Honderick T, Williams D, Seaberg D, et al. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med. 2003;21:39 42. 743. Hollander JE. Cocaine intoxication and hypertension. Ann Emerg Med. 2008;51:S18 20. 744. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation. 2010;122:2558 69. 745. Finkel JB, Marhefka GD. Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc. 2011;86:1198 207. 746. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine- induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897 903. 747. Dattilo PB, Hailpern SM, Fearon K, et al. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med. 2008;51:117 25. 748. Rangel C, Shu RG, Lazar LD, et al. Beta-blockers for chest pain associ- ated with recent cocaine use. Arch Intern Med. 2010;170:874 9. 749. Diercks DB, Kirk JD, Turnipseed SD, et al. Evaluation of patients with methamphetamine- and cocaine-related chest pain in a chest pain obser- vation unit. Crit Pathw Cardiol. 2007;6:161 4. 750. Watts DJ, McCollester L. Methamphetamine-induced myocardial infarc- tion with elevated troponin I. Am J Emerg Med. 2006;24:132 4. 751. Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coro- nary microvascular spasm. J Invasive Cardiol. 2007;19:E89 92. 752. Westover AN, Nakonezny PA, Haley RW. Acute myocardial infarc- tion in young adults who abuse amphetamines. Drug Alcohol Depend. 2008;96:49 56. 753. Parodi O, Maseri A, Simonetti I. Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit. Br Heart J 1979; 41:167 74. 754. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-con- trolled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol. 1993;21:1365 70. 755. Lombardi M, Morales MA, Michelassi C, et al. Efficacy of isosorbide- 5-mononitrate versus nifedipine in preventing spontaneous and ergonovine- induced myocardial ischaemia. A double-blind, placebo-controlled study. Eur Heart J. 1993;14:845 51. 756. Fukumoto Y, Yasuda S, Ito A, et al. Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlo- dipine. J Cardiovasc Pharmacol. 2008;51:253 7. 757. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844 8. 758. Kugiyama K, Ohgushi M, Sugiyama S, et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic cor- onary arteries in coronary spastic angina. Am J Cardiol. 1997;79:606 10. 759. Tani S, Nagao K, Anazawa T, et al. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study. J Cardiovasc Pharmacol. 2008;52:28 34. 760. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-meth- ylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol. 2008;51:1742 8. 761. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coro- nary spasm. Circulation. 1993;87:76 9. 762. Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. Am Heart J. 1992;124:32 8. 763. Yamagishi M, Ito K, Tsutsui H, et al. Lesion severity and hypercholester- olemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J. 2003;67:1029 35. 764. Koizumi T,Yokoyama M, Namikawa S, et al. Location of focal vasospasm provoked by ergonovine maleate within coronary arteries in patients with vasospastic angina pectoris. Am J Cardiol. 2006;97:1322 5. 765. Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008;52:523 7. 766. Cheng CW,Yang NI, Lin KJ, et al. Role of coronary spasm for a positive noninvasive stress test result in angina pectoris patients without hemo- dynamically significant coronary artery disease. Am J Med Sci. 2008; 335:354 62. 767. Wakabayashi K, Suzuki H, Honda Y, et al. Provoked coronary spasm predicts adverse outcome in patients with acute myocardial infarction: a novel predictor of prognosis after acute myocardial infarction. J Am Coll Cardiol. 2008;52:518 22. 768. OzakiY, Keane D, Serruys PW. Fluctuation of spastic location in patients with vasospastic angina: a quantitative angiographic study. J Am Coll Cardiol. 1995;26:1606 14. 769. Kusama Y, Kodani E, Nakagomi A, et al. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management. J Nippon Med Sch. 2011;78:4 12. 770. Ogawa H, Yasue H, Oshima S, et al. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation. 1989;80:1617 26. 771. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. Circulation. 2009;119:2531 4. 772. Kim PJ, Seung KB, Kim DB, et al. Clinical and angiographic characteris- tics of acute myocardial infarction caused by vasospastic angina without organic coronary heart disease. Circ J. 2007;71:1383 6. 773. Herrmann J, Kaski J, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J. 2012;33:2771 82. 774. Cannon ROI, Epstein SE. Microvascular angina as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61:1338 43. 775. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109:2993 9. 776. Doyle M, Weinberg N, Pohost GM, et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI- sponsored WISE (Women s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging. 2010;3:1030 6. 777. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation. 2004;109:568 72. 778. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124:1414 25. 779. Lanza GA, Sestito A, Sgueglia GA, et al. Current clinical features, diag- nostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol. 2007;118:41 7. 780. Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126:579 88. 781. Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular mag- netic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242 9. 782. Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocar- dial scar by contrast-enhanced cardiac magnetic resonance imaging in patients with troponin-positive chest pain and minimal angiographic coronary artery disease. Am J Cardiol. 2006;97:768 71. 783. Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with nor- mal coronary arteries: a role for MRI? Clin Chem. 2007;53:995 6. 784. Rosen SD, Uren NG, Kaski JC, et al. Coronary A vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation. 1994;90:50 60. 785. Bugiardini R, Bairey Merz CN. Angina with normal coronary arteries: a changing philosophy. JAMA. 2005;293:477 84. 786. Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol. 1995;25:807 14. 787. Ong P, Athanasiadis A, Borgulya G, et al. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syn- drome) study follow-up. J Am Coll Cardiol. 2011;57:147 52. 788. Cannon RO III, Watson RM, Rosing DR, et al. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol. 1985;56:242 6. 789. Bugiardini R, Borghi A, Biagetti L, et al. Comparison of verapamil ver- sus propranolol therapy in syndrome X. Am J Cardiol. 1989;63:286 90. 790. Maseri A. Ischemic Heart Disease: A Rational Basis for Clinical Practice and Clinical Research. New York, NY: Churchill Livingstone, 1995. 791. Lerman A, Burnett JC Jr., Higano ST, et al. Long-term L-arginine sup- plementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123 8. 792. Rosano GM, Peters NS, Lefroy D, et al. 17-beta-Estradiol therapy less- ens angina in postmenopausal women with syndrome X. J Am Coll Cardiol. 1996;28: 1500 5. 793. Mosca L. Cardiology patient page. Heart disease prevention in women. American Heart Association. Circulation. 2004;109:e158 60. tion: aggressive vs. conservative therapy. J Invasive Cardiol. 2010;22:222 8. 795. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takot-subo) cardiomyopathy. JAMA. 2011;306:277 86. 796. Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118:397 409. 797. Eitel I, Behrendt F, Schindler K, et al. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. Eur Heart J. 2008;29:2651 9. 798. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55:333 41. 799. Dote K, Sato H, Tateishi H, et al. [Myocardial stunning due to simul- taneous multivessel coronary spasms: a review of 5 cases]. J Cardiol. 1991;21:203 14. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e413 800. Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible car- diomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472 9. 801. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako- Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarc- tion. Am Heart J. 2008;155:408 17. 802. Akashi YJ, Goldstein DS, Barbaro G, et al. Takotsubo cardiomyopathy: a newformofacute,reversibleheartfailure.Circulation.2008;118:2754 62. 803. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539 48. 804. Elesber AA, Prasad A, Bybee KA, et al. Transient cardiac apical balloon- ing syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol. 2006;47:1082 3. 805. Elesber AA, Prasad A, Lennon RJ, et al. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007;50:448 52. 806. Ito K, Sugihara H, Katoh S, et al. Assessment of Takotsubo (ampulla) car- diomyopathy using 99mTc-tetrofosmin myocardial SPECT comparison with acute coronary syndrome. Ann Nucl Med. 2003;17:115 22. 807. Choy B, Hansen E, Moss AJ, et al. Relation of body mass index to sud- den cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol. 2010;105:581 6. 808. Mahaffey KW, Tonev ST, Spinler SA, et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123 33. 809. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled- release, phentermine plus topiramate combination on weight and asso- ciated comorbidities in overweight and obese adults (CONQUER): a randomised,placebo-controlled,phase3trial.Lancet.2011;377:1341 52. 810. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-con- trolled, phase 3 extension study. Am J Clin Nutr. 2012;95:297 308. 811. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067 77. 812. Busetto L, De SF, Pigozzo S, et al. Long-term cardiovascular risk and coronary events in morbidly obese patients treated with laparoscopic gas- tric banding. Surg Obes Relat Dis. 2013. 813. Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. 814. Ozturk B, Tacoy G, Coskun U, et al. Gemcitabine-induced acute coro- nary syndrome: a case report. Med Princ Pract. 2009;18:76 80. 815. Criscitiello C, Metzger-Filho O, Saini KS, et al. Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res. 2012;14:209. 816. Chalubinski M, Wojdan K, Dorantowicz R, et al. Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - emerging perspectives of immunomodulation. Arch Med Sci. 2013;9:159 65. 817. American Heart Association. Get With the Guidelines. 2009. Available at: http://www.heart.org/HEARTORG/HealthcareResearch/ GetWithThe GuidelinesHFStroke/Get-With-The-Guidelines HFStroke_ UCM_001099_SubHomePage.jsp. Accessed August 28, 2014. 818. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment eleva- tion acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569 78. 819. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2008;52:2113 7. 820. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2008;118:2662 6. 821. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST- elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2008;118:2596 648. 822. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2008;358:231 40. 823. National Cardiovascular Data Registry. Action Registry GWTG. 2009. Available at: http://www.ncdr.com/webncdr/ACTION/Default.aspx. Accessed June 10, 2009. 824. QualityNet.com. Measure Comparison (Inpatient Hospital Quality Measures). 2009. Available at: http://www.qualitynet.org/dcs/Conte cid=1138900297065. Accessed June 10, 2009. 825. The Joint Commission. Acute Myocardial Infarction Core Measure Set. 2009. Available at: http://www.jointcommission.org/core_measure_sets. aspx. Accessed August 28, 2014. 826. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of ran- domized trials of disease management programs in heart failure. Am J Med. 2001;110:378 84. 827. Coleman K, Austin BT, Brach C, et al. Evidence on the chronic care model in the new millennium. Health Aff (Millwood). 2009;28:75 85. KEY WORDS: AHA Scientific Statements acute coronary syndrome angina, unstable antiplatelet agents coronary artery bypass graft electrocardiography ischemia myocardial infarction percutaneous coronary intervention troponin Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2014 AHA/ACC Guideline for the Management of Patients With Non-St-Elevation Acute Coronary Syndromes Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Ezra A. Amsterdam (Chair) University of California (Davis) Medical Center, Division of Cardiology Professor None None None None None None None Nanette K. Wenger (Vice Chair) Emory University, School of Medicine Professor of Medicine (Cardiology) Abbott Amgen AstraZeneca Gilead Sciences Janssen Pharmaceuticals Medtronic Merck Pfizer None None Abbott Eli Lilly Gilead Sciences Merck Pfizer None None All sections and 8. Ralph G. Brindis University of California, San Francisco Department of Medicine and the Phillip R. Lee Institute for Health Policy Studies Clinical Professor of Medicine None Volcano None None None None None Donald E. Casey, Jr Atlantic Health Vice President of Health and Chief Medical Officer None None None None None None None Theodore G. Ganiats University of California, San Diego School of Medicine Executive Director of Health Services Research Center None None None None None None None David R. Holmes, Jr Mayo Clinic Consultant, Cardiovascular Diseases None None None None None None None Allan S. Jaffe Mayo Clinic, Cardiovascular Division Professor of Medicine Abbott Alere Amgen Beckman- Coulter Critical Diagnostics ET Healthcare Ortho Clinical Diagnostic Radiometer Roche Thermo-Fishert Trinity None None None None None All sections 7.6, and 8. Hani Jneid Baylor College of Medicine The Michael E. DeBakey VA Medical Center Assistant Professor of Medicine None None None None None None None (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e415 Rosemary F. Kelly University of Minnesota Professor of Surgery; VA Medical Center Chief, Cardiothoracic Surgery None None None None None None None Michael C. Kontos Virginia Commonwealth University, Pauley Heart Center Medical Director, Coronary Intensive Care Unit, and Associate Professor, Internal Medicine Astellas General Electric Ikaria Prevencio Sanofi-aventis Wellpoint/Anthem Astellas AstraZeneca None None Astellas Eli Lilly Merck Novartis None All sections Glenn N. Levine Baylor College of Medicine Professor of Medicine; Director, Cardiac Care Unit None None None None None None None Philip R. Liebson Rush University Medical Center McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine None None None None None None None Debabrata Mukherjee Texas Tech University Health Sciences Center Chief, Cardiovascular Medicine None None None None None None None Eric D. Peterson Duke University Medical Center Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute Director Boehringer Ingelheim Genentech Janssen Pharmaceuticals Johnson & Johnson Merck None None Eli Lilly Johnson & Johnson Janssen Pharmaceuticals DCRI has numerous grants and contracts sponsored by industry that are relevant to the content of this CPG. Dr. Peterson participated in discussions but recused himself from writing or voting, in accordance with ACC/AHA policy. See comprehensive RWI table for a complete list of companies pertaining to this organization. None All sections Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* (Continued) Marc S. Sabatine Brigham and Women s Hospital, Chairman TIMI Study Group, Division of Cardiovascular Medicine; Harvard Medical School Professor of Medicine Amgen AstraZeneca Bristol-Myers Squibb Merck Pfizer Sanofi-aventis None None Abbott Laboratories Amgen AstraZeneca Bristol-Myers Squibb Critical Diagnostics Daiichi-Sankyo Genzyme GlaxoSmithKline Nanosphere Roche Diagnostics Sanofi-aventis Takeda AstraZeneca Daiichi-Sankyo Gilead Johnson & Johnson BRAHMS Proventys Siemens Singulex None All sections except and 8. Richard W. Smalling University of Texas, Health Science Center at Houston Professor and Director of Interventional Cardiovascular Medicine; James D. Woods Distinguished Chair in Cardiovascular Medicine Gilead Maquet None None Cordis E-valve Abbott Vascular Edwards Lifesciences Gilead Maquet Datascope Cordis E-valve None All sections except 7.8, and 8. Susan J. Zieman National Institute on Aging/NIH, Geriatrics Branch, Division of Geriatrics and Clinical Gerontology Medical Officer None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the GWC during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; ore) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Writing members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text CPG. Significant relationship. No financial benefit. ACC indicates American College of Cardiology, AHA, American Heart Association, BMS, Bristol-Myers Squibb; CPG, clinical practice guideline; DCRI, Duke Clinical Research Institute; NIH, National Institutes of Health; NYU, New York University; RWI, relationships with industry and other entities; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs. Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e417 Appendix 2. 